2016 Press Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013
DateTitle 
02/04/16Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif., Feb. 4, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: Leerink Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016 in New York, NY; Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9, 2016 in Boston, MA; 28th Annual ROTH Conference on Monday, March 14, 2016 in Dana Point, CA; ... 
Printer Friendly Version
01/19/16Akcea Therapeutics Appoints Louis St. L. O'Dea as Chief Medical Officer
Appointment adds depth in clinical and regulatory leadership CAMBRIDGE, Mass., Jan. 19, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, today announced the appointment of Louis St. L. O'Dea, MB, BCh, BAO, FRCP(C) as the company's Chief Medical Officer.  Dr. O'Dea will lead medical, clinical, and regulatory functions in support of volanesorsen and will al... 
Printer Friendly Version
01/13/16Ionis Pharmaceuticals Announces that GSK has Initiated a Phase 1 Study of IONIS-HBV-L Rx
Ionis Earns $1.5M Milestone Payment CARLSBAD, Calif., Jan. 13, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that GSK has initiated a Phase 1 study of IONIS-HBV-LRx.  Ionis earned a $1.5 million milestone payment from GSK related to the initiation of this study.  IONIS-HBV-LRx, which was previously referred to as ISIS-GSK6-LRx, is a drug Ionis is developing with GSK for the treatment of patients with hepatitis B virus (HBV).  IONIS-HBV-LRx incorporates Ionis'... 
Printer Friendly Version
01/12/16Ionis Pharmaceuticals Completes Target Enrollment for Nusinersen Phase 3 Study, CHERISH, in Children with Spinal Muscular Atrophy
Ionis Earns $2.15M Milestone Payment from Biogen as Nusinersen Advances CARLSBAD, Calif., Jan. 12, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned a milestone payment of $2.15 million from Biogen for completing the target enrollment of the Phase 3 CHERISH study. The study is designed to support marketing approval of nusinersen in children with spinal muscular atrophy (SMA).   "Achieving our target enrollment number in CHERISH brings us ... 
Printer Friendly Version
01/11/16Ionis Pharmaceuticals Revises 2015 Financial Guidance and Provides Pipeline Update in Conjunction with J.P. Morgan Conference
Significantly improved net operating loss and increased cash projected CARLSBAD, Calif., Jan. 11, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the Company expects to significantly improve upon its financial guidance for 2015.  The Company expects to end 2015 with a pro forma net operating loss (NOL) in the low $20 million range and more than $775 million in cash.  "Over the past several years, we have created a strong and consistent financial foun... 
Printer Friendly Version
01/05/16Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington's Disease
First therapy designed to directly target the cause of disease CARLSBAD, Calif., Jan. 5, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to IONIS-HTTRx for the treatment of patients with Huntington's disease (HD). IONIS-HTTRx is the first therapy to enter clinical development that is designed to directly target the cause of the disease by reducing the production of the protein respon... 
Printer Friendly Version
01/04/16Ionis Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference
CARLSBAD, Calif., Jan. 4, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016 at 2:30 p.m. PT in San Francisco, CA. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.ionispharma.com. A replay will be available on the Ioni... 
Printer Friendly Version